Back to top
more

Moderna (MRNA)

(Real Time Quote from BATS)

$54.34 USD

54.34
1,340,692

-0.29 (-0.53%)

Updated Nov 4, 2024 11:48 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Moderna (MRNA) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

Moderna (MRNA) concluded the recent trading session at $137.90, signifying a -1.52% move from its prior day's close.

Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine

by Zacks Equity Research

Novavax (NVAX) seeks FDA???s approval to update its COVID-19 vaccine for the 2024-2025 fall season against current circulating strains, including KP.2 and KP.3.

Moderna's (MRNA) Next-Gen COVID-19 Jab Study Meets Efficacy Goal

by Zacks Equity Research

Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.

Moderna (MRNA) COVID-Flu Combo Jab Meets Late-Stage Study Goal

by Zacks Equity Research

Data from a late-stage study shows that Moderna's (MRNA) experimental COVID-19-influenza combination vaccine generates higher immune responses when compared to co-administered licensed flu and COVID vaccines.

Moderna (MRNA) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $148.59, marking a -1.6% move from the previous day.

Moderna (MRNA) Submits Updated COVID-19 Jab to FDA for Review

by Zacks Equity Research

Moderna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1 to the FDA for the upcoming vaccination season.

GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years

by Zacks Equity Research

GSK's Arexvy becomes the first RSV vaccine approved for adults aged 50-59 who are at high risk.

Acadia (ACAD) Up 0.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Halozyme Therapeutics (HALO) Up 8.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sweta Killa headshot

5 Stocks Propelling S&P 500 to 25th Record High

by Sweta Killa

The S&P 500 touches a record high for the 25th time this year, powered by technology stocks. We have highlighted five technology stocks, HPE, MRNA, AVGO, MU and LRCX, leading the way higher in the latest trading session.

Should First Trust NASDAQ-100 Equal Weighted ETF (QQEW) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for QQEW

Sundeep Ganoria headshot

FDA Panel to Consider Updating COVID-19 Jabs for New Virus Strains

by Sundeep Ganoria

An FDA panel meeting is scheduled on Jun 5 to consider if COVID-19 vaccines should be updated to target the WHO-recommended JN.1 variant or the KP.2 variant which is the currently dominating strain in the country.

Company News for June 4, 2024

by Zacks Equity Research

Companies In The Article Are:NVDA, MRK,MRNA, SPOT, SRCL and WM

Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine

by Zacks Equity Research

The RSV vaccine is Moderna???s (MRNA) second FDA-approved product. Once the vaccine secures the CDC's recommendation, it will be launched in the 2024-2025 respiratory virus season.

The Zacks Analyst Blog Highlights NVIDIA, Constellation Energy, Micron Technology, Moderna and Qualcomm

by Zacks Equity Research

NVIDIA, Constellation Energy, Micron Technology, Moderna and Qualcomm are part of the Zacks top Analyst Blog.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Sweta Killa headshot

Nasdaq Tops 17K: 5 Best-Performing Stocks in ETF YTD

by Sweta Killa

The Nasdaq Composite Index topped the 17,000 level for the first time. We have highlighted five best-performing stocks of QQQ this year that led the way higher in the portfolio.

Moderna (MRNA) Stock Outperformed Industry YTD: Here's Why

by Zacks Equity Research

Shares of Moderna (MRNA) are being driven by encouraging pipeline updates and plans for potential product launches.

Sundeep Ganoria headshot

Vaccine Stocks Rise on Growing Threat of Bird Flu Infections

by Sundeep Ganoria

The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.

Sanofi (SNY) Signs Deal for AI-Powered Drug Development

by Zacks Equity Research

Sanofi (SNY) inks collaboration deal with Formation Bio and OpenAI to build AI-powered software to advance drug development and create new medicines.

Why Novavax (NVAX) Stock Price Appreciated 14% on Monday

by Zacks Equity Research

Novavax (NVAX) surges after one of its top shareholders drops a proxy campaign against the company. This withdrawal is in sync with the company???s recently signed multi-billion-dollar deal with Sanofi.

Here's Why Merck (MRK) Stock Has Outperformed Industry YTD

by Zacks Equity Research

Merck (MRK) stock is being driven by the strong sales of key products like Keytruda and Gardasil and positive pipeline and regulatory developments.

The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers

by Zacks Equity Research

Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.

Ekta Bagri headshot

Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY

by Ekta Bagri

Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.

Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility

by Zacks Equity Research

Merck (MRK) discontinues the Keytruda plus vibostolimab co-formulation arm of a phase III study due to a higher rate of patient discontinuation.